MNG1177
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.534
- G2M_CHECKPOINT+0.471
- PROTEIN_SECRETION+0.410
- MYC_TARGETS_V1+0.377
- MYC_TARGETS_V2+0.374
- MITOTIC_SPINDLE+0.361
- UNFOLDED_PROTEIN_RESPONSE+0.263
- DNA_REPAIR+0.206
- MTORC1_SIGNALING+0.172
- PI3K_AKT_MTOR_SIGNALING+0.143
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.421
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.378
- INTERFERON_ALPHA_RESPONSE-0.364
- MYOGENESIS-0.355
- KRAS_SIGNALING_DN-0.349
- APICAL_SURFACE-0.325
- INTERFERON_GAMMA_RESPONSE-0.324
- COAGULATION-0.321
- APICAL_JUNCTION-0.313
- ESTROGEN_RESPONSE_LATE-0.236
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1178 | — | — | 0.935 |
| 2 | SRR12475130 | — | — | 0.896 |
| 3 | R143 | — | — | 0.896 |
| 4 | R181 | — | — | 0.882 |
| 5 | SRR12475147 | — | — | 0.873 |
| 6 | SRR11296736 | — | — | 0.869 |
| 7 | 2B4FA61A-C1A7-49BD-9438-2865D386EAF2 | — | — | 0.869 |
| 8 | MDT-AP-3297 | Med | Medulloblastoma | 0.868 |
| 9 | C6A16A8F-0AB7-42E9-A068-15EECF2912D3 | — | — | 0.866 |
| 10 | BS_TV5B86ZD | Embryonal tumors | — | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.534 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.471 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.377 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.374 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.361 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.263 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.206 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.172 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.143 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.129 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.120 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.036 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.025 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.009 | Inavolisib | — uncovered |